Your browser is no longer supported. Please, upgrade your browser.
Settings
ABBV AbbVie Inc. daily Stock Chart
ABBV [NYSE]
AbbVie Inc.
IndexS&P 500 P/E16.45 EPS (ttm)3.72 Insider Own0.10% Shs Outstand1.63B Perf Week-0.21%
Market Cap99.75B Forward P/E11.18 EPS next Y5.47 Insider Trans-3.53% Shs Float1.62B Perf Month-0.73%
Income6.08B PEG1.07 EPS next Q1.19 Inst Own69.40% Short Float2.06% Perf Quarter0.55%
Sales25.24B P/S3.95 EPS this Y185.20% Inst Trans0.01% Short Ratio4.09 Perf Half Y-2.43%
Book/sh3.96 P/B15.44 EPS next Y13.50% ROA10.10% Target Price69.94 Perf Year8.79%
Cash/sh4.87 P/C12.55 EPS next 5Y15.39% ROE117.50% 52W Range49.70 - 66.82 Perf YTD-1.36%
Dividend2.56 P/FCF25.39 EPS past 5Y3.50% ROI16.90% 52W High-8.49% Beta1.59
Dividend %4.19% Quick Ratio1.60 Sales past 5Y7.90% Gross Margin77.30% 52W Low23.04% ATR0.95
Employees28000 Current Ratio1.80 Sales Q/Q8.20% Oper. Margin36.20% RSI (14)46.15 Volatility1.50% 1.50%
OptionableYes Debt/Eq5.77 EPS Q/Q30.90% Profit Margin24.10% Rel Volume0.82 Prev Close61.38
ShortableYes LT Debt/Eq5.76 EarningsJan 27 BMO Payout61.00% Avg Volume8.16M Price61.15
Recom2.50 SMA20-1.35% SMA500.05% SMA2000.00% Volume6,720,016 Change-0.37%
Oct-31-16Downgrade Credit Suisse Outperform → Neutral
Oct-18-16Initiated Leerink Partners Mkt Perform $70
Sep-08-16Downgrade JP Morgan Overweight → Neutral
Sep-02-16Initiated Raymond James Outperform $82
Jun-08-16Downgrade Morgan Stanley Overweight → Equal-Weight
Apr-06-16Initiated Societe Generale Sell $47
Mar-15-16Initiated Deutsche Bank Hold $63
Feb-23-16Upgrade Citigroup Neutral → Buy
Dec-01-15Downgrade Barclays Overweight → Equal Weight $73 → $72
Nov-02-15Upgrade Morgan Stanley Equal-Weight → Overweight
Oct-23-15Reiterated UBS Buy $81 → $78
Sep-28-15Upgrade Citigroup Sell → Neutral
Jul-22-15Initiated Sun Trust Rbsn Humphrey Buy
Jun-17-15Initiated Piper Jaffray Overweight
Jun-08-15Reiterated Jefferies Buy $86 → $90
May-28-15Resumed Morgan Stanley Equal-Weight $72
May-27-15Resumed JP Morgan Overweight $75
Jan-06-15Reiterated UBS Buy $72 → $76
Nov-26-14Reiterated Argus Buy $65 → $85
Nov-14-14Initiated Deutsche Bank Buy $80
Jan-22-17 05:41PM  AbbVie Gets FDA Approval for Lymphoma Drug
06:42AM  3 Incredibly Cheap High-Yield Dividend Stocks at Motley Fool
Jan-21-17 10:33AM  10 Best Dividend-Paying Stocks for 2017 at Kiplinger
12:01AM  [$$] Payout Appeal at Barrons.com
Jan-20-17 04:30PM  Amgen Could Gouge 'Top Pick' AbbVie With Humira Biosimilar: Jefferies
02:52PM  Novartis (NVS) Q4 Earnings: Stock Likely to Disappoint?
02:41PM  4 Drug Stocks Poised to Surprise this Earnings Season
11:17AM  Heres Whats Important About The Latest AbbVie Inc (ABBV) Approval at Insider Monkey
08:45AM  Celgene (CELG) Q4 Earnings: Will the Stock Pull a Surprise?
08:15AM  Blog Coverage AbbVie Received FDA Approval for Treatment for Marginal Zone Lymphoma Accesswire
08:14AM  Abbvie (ABBV) Imbruvica Approved in Lymphoma Indication
08:02AM  Are You Undervaluing These 3 Biopharmas' Pipelines? at Motley Fool
07:38AM  [$$] AbbVie Hikes the Price of Humira: Stock May Jump at Barrons.com
Jan-19-17 03:47PM  4 Best Marijuana Stocks to Play the Green Rush
03:43PM  Boehringer Ingelheim's Humira Biosimilar Under Review by EMA, FDA
09:12AM  How Johnson & Johnson Beat Every Other Big Pharma Stock in 2016 at Motley Fool
08:40AM  Biogen (BIIB) Q4 Earnings: What's in Store for the Stock?
07:00AM  U.S. FDA Approves IMBRUVICA® (ibrutinib) as First Treatment Specifically Indicated for Relapsed/Refractory Marginal Zone Lymphoma (MZL) - a Rare Type of Non-Hodgkin's Lymphoma PR Newswire
Jan-18-17 11:29AM  Top 4 Medicinal Marijuana Stocks for 2017 at Investopedia
10:40AM  Orphan Drugs Among 2015's Top 10 Best-Selling Medications
Jan-17-17 07:30AM  [$$] Biotech M&A Deals Expected to Increase in 2017 at The Wall Street Journal
Jan-16-17 04:08PM  Adient Stock: Still Undervalued After Johnson Controls Spinoff
02:13PM  3 Bold Bets on the Future of Healthcare at Motley Fool
Jan-13-17 10:43AM  AbbVie, Inc. Value Analysis (NYSE:ABBV) : January 13, 2017
09:55AM  Coherus Offers Positive Phase III Data on Humira Biosimilar
Jan-12-17 03:22PM  Investors in big pharma, biotech look to ride out Trump storm
09:37AM  12 Health Benefits of Medical Marijuana According To Publicly Traded Weed Companies at Insider Monkey
09:10AM  7 Reasons AbbVie's Stock Could Soar in 2017 at Motley Fool
07:58AM  AbbVie, Inc. breached its 50 day moving average in a Bearish Manner : ABBV-US : January 12, 2017
Jan-11-17 02:47PM  Entana Pharmaceuticals Releases Study Results of Hepatitis Treatment in Japanese Patients
09:13AM  Biotech Stock Roundup: ARIAD to be Acquired for $5.2B, Vertex Outlook Falls Short
Jan-10-17 01:20PM  Emergent Technologies Pure MHC Explores A New Collaboration With AbbVie Inc (ABBV) at Insider Monkey
09:00AM  AbbVie to Host Fourth-Quarter 2016 Earnings Conference Call PR Newswire
08:50AM  AbbVie's HCV Combo Favorable in Japanese Phase III Study
02:08AM  Japan's Takeda ready for fresh acquisitions after $5.2 bln Ariad deal
Jan-09-17 06:28PM  The Best DRIP Stocks: 15 No-Fee Dividend Aristocrats
09:00AM  Pure MHC to Partner with AbbVie on Oncology Research Business Wire
08:05AM  AbbVie, Genomics Medicine Ireland and WuXi NextCODE Announce Landmark Population Genomics Alliance PR Newswire
08:00AM  AbbVie Announces Four New Global Research Collaborations Focused on Advancing Next-Generation Science PR Newswire
07:00AM  Eight Weeks of Treatment with AbbVie's Investigational, Pan-Genotypic, Ribavirin-free Regimen of Glecaprevir/Pibrentasvir (G/P) for Chronic Hepatitis C Achieved High SVR Rates in Genotype 1 Japanese Patients PR Newswire
06:55AM  Will Johnson & Johnson Shock Investors with a Spin-off in 2017? at Motley Fool
06:09AM  Pfizer's Humira Biosimilar Meets Primary Endpoint in Study (Revised)
Jan-05-17 05:42PM  Top 7 Dividend Health Care Stocks
05:26PM  Pfizer Unveils Positive Results from Study of Potential Humira Biosimilar
05:02PM  ABBVIE INC. Files SEC form 8-K, Change in Directors or Principal Officers
02:55PM  Gilead Sciences Inc.'s Biggest Failure in 2016 at Motley Fool
02:50PM  Here's who won big in last year's top 10 VC-backed startup sales in the Bay Area at bizjournals.com
Jan-04-17 03:29PM  [$$] Pennsylvania Is Ordered to Provide Hepatitis C Drug to Inmate at The Wall Street Journal
12:44PM  Unusual activity: Bulls bet on Disney & AbbVie
11:52AM  These Biotech Stocks Could Run in 2017
Jan-03-17 01:14PM  Mylan NV (MYL), AbbVie Inc (ABBV) Sanofi SA (ADR) (SNY) In Spotlight Over Price Hikes at Insider Monkey
12:03PM  Discounted Stocks: Apple, Accenture, Aaron's
09:24AM  6 Top Stocks to Buy in January at Motley Fool
07:36AM  Harvoni: Gilead Sciences Blockbuster HCV Drug
Jan-02-17 11:47PM  Drug Pricing Report Shows Limits of Transparency Push at The Wall Street Journal
Dec-31-16 09:01AM  Drug Pricing Report Shows Limits of Transparency Push at The Wall Street Journal
Dec-30-16 04:36PM  Which Top 5 Biotech Stocks In 2016 Are Slated For Triple-Digit Gains?
12:45PM  Which Top 5 Biotech Stocks In 2016 Are Slated For Triple-Digit Gains?
08:40AM  AbbVie's Humira and Imbruvica Drive Performance in 2016
Dec-29-16 11:13AM  Dividend Stock Picks Could Look Even Better in Coming Weeks
10:36AM  When Will the Biosimilar for Enbrel Be Available?
07:35AM  Enbrel Sales Were Flat in 3Q16
Dec-28-16 10:25AM  Short Interest Rises in Major Pharma
08:52AM  Morning Movers: Bank of New York Gains on Upgrade; Galena Biopharma Soars at Barrons.com
Dec-27-16 03:53PM  3 Biggest Risks for AbbVie in 2017 at Motley Fool
10:25AM  Jefferies Makes Huge Year-End Addition to Franchise Picks List at 24/7 Wall St.
08:30AM  Top 10 Dividend Stocks You Need to Buy Now to Prepare for 2017
Dec-26-16 02:07PM  3 Big Pharma Stocks With the Fastest-Growing Dividends at Motley Fool
09:03AM  3 Top High-Yield Dividend Stocks to Buy in 2017 at Motley Fool
08:36AM  3 High-Yield Dividend Stocks Wealthy Investors Should Consider Buying at Motley Fool
Dec-23-16 01:24PM  Billionaire Druckenmillers Top Dividend Stock Picks at Insider Monkey
11:45AM  The 10 Best Dividend Aristocrats for 2017 and Beyond
09:06AM  Celgene, Evotec Target Unmet Demand in Neurodegenerative Segment
08:25AM  Roche (RHHBY) Hemophilia A Drug Positive in Phase III
Dec-22-16 08:00AM  AbbVie to Present at the 35th Annual J.P. Morgan Healthcare Conference PR Newswire
Dec-21-16 03:52PM  Forget Gilead Sciences Inc.: These 3 Stocks Are Better Buys at Motley Fool
11:22AM  AbbVie Inc (ABBV) Awaits NDA Approval For Hepatitis C Treatment at Insider Monkey
09:30AM  The Zacks Analyst Blog Highlights: AbbVie, Union Pacific, U.S. Bancorp, Baker Hughes and Southwest Airlines
Dec-20-16 03:06PM  3 Dividend Stocks to Put on Your Shopping List at Motley Fool
11:06AM  Analyst Reports for Union Pacific, AbbVie & U.S. Bancorp
09:40AM  AbbVie (ABBV) Submits NDA for Next-Gen HCV Combo in US
09:36AM  AbbVie Files for Approval of Hepatitis C Treatment in the US
Dec-19-16 04:14PM  Bristol-Myers Will Gain In Lung Cancer Square-Off Vs. Merck: Jefferies
02:06PM  Forget Marijuana Stocks: Buy These 3 Biotech Stocks Instead at Motley Fool
10:30AM  J&J Files sBLA for Plaque Psoriasis in Adolescent Patients
08:00AM  AbbVie Submits New Drug Application to U.S. FDA for its Investigational Regimen of Glecaprevir/Pibrentasvir (G/P) for the Treatment of All Major Genotypes of Chronic Hepatitis C PR Newswire
Dec-18-16 01:36PM  3 Low-Volatility Biotech Stocks to Buy at Motley Fool
Dec-16-16 12:56PM  Billionaire Larry Robbins Knows How To Pick Mega-Cap Stocks at Insider Monkey
08:29AM  Gilead Must Pay Merck $2.5 Billion For Hep C Patent; Agios Stock Anemic
08:03AM  Is This Gilead Sciences' Biggest Mistake in 2016? at Motley Fool
Dec-15-16 05:37PM  How Risky Is Gilead Sciences Inc.? at Motley Fool
12:35PM  Sarilumab: Leading Rheumatoid Arthritis Therapy in the Future?
Dec-14-16 08:05AM  Loss of Patent Protection to Drag Pfizers Top Line
12:24AM  [$$] Sanofi Is in Talks for Deal With Actelion Pharmaceuticals at The Wall Street Journal
Dec-13-16 11:31PM  [$$] Sanofi in Talks for Deal With Actelion Pharmaceuticals at The Wall Street Journal
05:14PM  Express Scripts to Include Harvoni in Hepatitis Cure Value Program
Dec-12-16 03:04PM  Marijuana Investing in 2017: 5 Numbers Everyone Should Know at Motley Fool
02:05PM  3 Biotech Buybacks With the Biggest Bang for the Buck at Motley Fool
12:46PM  With Obamacare repealed, 1 in 4 adults could be uninsurable due to a pre-existing condition at MarketWatch
11:18AM  AbbVie Needs a Nudge to Get the Bull Going Again
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceutical products worldwide. The company offers HUMIRA, a biologic therapy administered as a subcutaneous injection to treat autoimmune diseases; IMBRUVICA, an oral therapy for the treatment of chronic lymphocytic leukemia; and VIEKIRA PAK, an interferon-free therapy, with or without ribavirin, for adults with genotype 1 chronic hepatitis. It also provides Kaletra, an anti-HIV-1 medicine used with other anti-HIV-1 medications as a treatment that maintains viral suppression in HIV-1 patients; Norvir, a protease inhibitor indicated in combination with other antiretroviral agents to treat HIV-1; and Synagis to prevent respiratory syncytial virus infection in high risk infants. In addition, the company offers AndroGel, a testosterone replacement therapy for males diagnosed with symptomatic low testosterone; Creon, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid to treat hypothyroidism; and Lupron, a product for the palliative treatment of prostate cancer, and endometriosis and central precocious puberty, as well as for the treatment of patients with anemia. Further, it provides Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Sevoflurane, an anesthesia product for human use; TriCor, Trilipix, and Niaspan to treat metabolic conditions characterized by high cholesterol and/or high triglycerides; and Zemplar to treat secondary hyperparathyroidism. The company sells its products to wholesalers, distributors, government agencies, health care facilities, specialty pharmacies, and independent retailers from its distribution centers and public warehouses. AbbVie Inc. has strategic collaboration with C2N Diagnostics; Calico Life Sciences LLC; Infinity Pharmaceuticals, Inc.; Ablynx NV; Galapagos NV; Alvine Pharmaceuticals, Inc.; and Zebra Biologics Inc. The company was incorporated in 2012 and is based in North Chicago, Illinois.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
CHASE WILLIAM JEVP, Chief Financial OfficerDec 02Option Exercise27.296,600180,114178,970Dec 02 05:08 PM
CHASE WILLIAM JEVP, Chief Financial OfficerDec 02Sale59.196,600390,654172,370Dec 02 05:08 PM
HURWICH THOMAS A.VP, ControllerNov 16Option Exercise28.863,10089,47564,549Nov 18 05:39 PM
HURWICH THOMAS A.VP, ControllerNov 16Sale62.003,100192,20061,449Nov 18 05:39 PM
Schumacher Laura JExecutive Vice PresidentSep 07Sale65.0050,0003,250,000144,138Sep 09 05:38 PM
Schumacher Laura JExecutive Vice PresidentJun 24Option Exercise27.62186,1065,140,971380,244Jun 28 05:47 PM
Schumacher Laura JExecutive Vice PresidentJun 24Sale60.03186,10611,171,173194,138Jun 28 05:47 PM
GONZALEZ RICHARD AChairman of the Board and CEOJun 02Sale63.82285,95318,249,712338,421Jun 03 05:26 PM
GONZALEZ RICHARD AChairman of the Board and CEOMay 11Sale63.8039,0002,488,200338,421May 13 05:11 PM
HURWICH THOMAS A.VP, ControllerMay 10Option Exercise27.296,000163,74068,204May 12 05:44 PM
HURWICH THOMAS A.VP, ControllerMay 10Sale63.596,000381,54162,204May 12 05:44 PM
ALBAN CARLOSEVP, Commercial OperationsMay 10Sale63.5247,4383,013,262149,444May 12 05:39 PM
Schumacher Laura JExecutive Vice PresidentMar 08Sale56.0925,0001,402,341194,138Mar 08 05:23 PM
SALEKI-GERHARDT AZITASVP, OperationsFeb 05Option Exercise22.943,40077,9985,143Feb 09 05:13 PM